Generation of Optimized Consensus Sequences for Hepatitis C virus (HCV) Envelope 2 Glycoprotein (E2) by a Modified Algorithm: Implication for a Pan-genomic HCV Vaccine.

Q3 Biochemistry, Genetics and Molecular Biology
Reyhaneh Mohabati, Reza Rezaei, Nasir Mohajel, Mohammad Mehdi Ranjbar, Katayoun Samimi-Rad, Kayhan Azadmanesh, Farzin Roohvand
{"title":"Generation of Optimized Consensus Sequences for Hepatitis C virus (HCV) Envelope 2 Glycoprotein (E2) by a Modified Algorithm: Implication for a Pan-genomic HCV Vaccine.","authors":"Reyhaneh Mohabati, Reza Rezaei, Nasir Mohajel, Mohammad Mehdi Ranjbar, Katayoun Samimi-Rad, Kayhan Azadmanesh, Farzin Roohvand","doi":"10.18502/ajmb.v16i4.16743","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite the success of \"direct-acting antivirals\" in treating Hepatitis C Virus (HCV) infection, invention of a preventive HCV vaccine is crucial for global elimination of the virus. Recent data indicated the importance of the induction of Pangenomic neutralizing Antibodies (PnAbs) against heterogenic HCV Envelope 2(E2), the cellular receptor binding antigen, by any HCV vaccine candidate. To overcome HCVE2 heterogeneity, \"generation of consensus HCVE2 sequences\" is proposed. However, Consensus Sequence (CS) generating algorithms such as \"Threshold\" and \"Majority\" have certain limitations including \"Threshold-rigidity\" which leads to induction of undefined residues and insensitivity of the \"Majority\" towards the \"evolutionary cost of residual substitutions\".</p><p><strong>Methods: </strong>Herein, first a modification to the \"Majority\" algorithm was introduced by incorporating BLOSUM matrices. Secondly, the HCVE2 sequences generated by the \"Fitness\" algorithm (using 1698 sequences from genotypes 1, 2, and 3) was compared with those generated by the \"Majority\" and \"Threshold\" algorithms using several <i>in silico</i> tools.</p><p><strong>Results: </strong>Results indicated that only \"Fitness\" provided completely defined, gapless HCVE2s for all genotypes/subtypes, while considered the evolutionary cost of amino acid replacements (main \"Majority/Threshold\" limitations) by substitution of several residues within the generated consensuses. Moreover, \"Fitness-generated HCVE2 CSs\" were superior for antigenic/immunogenic characteristics as an antigen, while their positions within the phylogenetic trees were still preserved.</p><p><strong>Conclusion: </strong>\"Fitness\" algorithm is capable of generating superior/optimum HCVE2 CSs for inclusion in a pan-genomic HCV vaccine and can be similarly used in CS generation for other highly variable antigens from other heterogenic pathogens.</p>","PeriodicalId":8669,"journal":{"name":"Avicenna journal of medical biotechnology","volume":"16 4","pages":"268-278"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589427/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avicenna journal of medical biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ajmb.v16i4.16743","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Despite the success of "direct-acting antivirals" in treating Hepatitis C Virus (HCV) infection, invention of a preventive HCV vaccine is crucial for global elimination of the virus. Recent data indicated the importance of the induction of Pangenomic neutralizing Antibodies (PnAbs) against heterogenic HCV Envelope 2(E2), the cellular receptor binding antigen, by any HCV vaccine candidate. To overcome HCVE2 heterogeneity, "generation of consensus HCVE2 sequences" is proposed. However, Consensus Sequence (CS) generating algorithms such as "Threshold" and "Majority" have certain limitations including "Threshold-rigidity" which leads to induction of undefined residues and insensitivity of the "Majority" towards the "evolutionary cost of residual substitutions".

Methods: Herein, first a modification to the "Majority" algorithm was introduced by incorporating BLOSUM matrices. Secondly, the HCVE2 sequences generated by the "Fitness" algorithm (using 1698 sequences from genotypes 1, 2, and 3) was compared with those generated by the "Majority" and "Threshold" algorithms using several in silico tools.

Results: Results indicated that only "Fitness" provided completely defined, gapless HCVE2s for all genotypes/subtypes, while considered the evolutionary cost of amino acid replacements (main "Majority/Threshold" limitations) by substitution of several residues within the generated consensuses. Moreover, "Fitness-generated HCVE2 CSs" were superior for antigenic/immunogenic characteristics as an antigen, while their positions within the phylogenetic trees were still preserved.

Conclusion: "Fitness" algorithm is capable of generating superior/optimum HCVE2 CSs for inclusion in a pan-genomic HCV vaccine and can be similarly used in CS generation for other highly variable antigens from other heterogenic pathogens.

通过修改算法生成丙型肝炎病毒(HCV)包膜 2 糖蛋白(E2)的优化共识序列:泛基因组 HCV 疫苗的意义。
背景:尽管 "直接作用抗病毒药物 "在治疗丙型肝炎病毒(HCV)感染方面取得了成功,但发明一种预防性 HCV 疫苗对于在全球范围内消灭该病毒至关重要。最近的数据表明,任何丙型肝炎病毒候选疫苗都必须针对异源性丙型肝炎病毒包膜 2(E2)(细胞受体结合抗原)诱导泛基因组中和抗体(PnAbs)。为了克服 HCVE2 的异质性,有人提出了 "生成 HCVE2 共识序列"。然而,"阈值 "和 "多数 "等共识序列(Consensus Sequence,CS)生成算法有一定的局限性,包括 "阈值-刚性 "导致诱导未定义的残基,以及 "多数 "对 "残余取代的进化成本 "不敏感。其次,使用几种硅学工具,将 "Fitness "算法(使用来自基因型 1、2 和 3 的 1698 个序列)生成的 HCVE2 序列与 "Majority "和 "Threshold "算法生成的 HCVE2 序列进行比较:结果表明,只有 "Fitness "算法为所有基因型/亚型提供了完全定义的无间隙 HCVE2,同时考虑了氨基酸替换的进化成本("Majority/Threshold "算法的主要限制),在生成的同义词中替换了几个残基。此外,"Fitness 生成的 HCVE2 CSs "在作为抗原的抗原性/免疫原性特征方面更胜一筹,同时它们在系统发生树中的位置仍然保持不变:结论:"Fitness "算法能够生成优越/最佳的 HCVE2 CS,以纳入泛基因组 HCV 疫苗,并可同样用于生成其他异源病原体的其他高变异抗原的 CS。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Avicenna journal of medical biotechnology
Avicenna journal of medical biotechnology Biochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
2.90
自引率
0.00%
发文量
43
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信